When comparing the effect of the treatment with the SYK inhibitors on AML cell viability to the untreated control, we found a significant decrease in viability after treatment with the highest concentrations of fostamatinib, entospletinib, TAK-659, and RO9021 (Wilcoxon signed-rank test; p = 0.0025, 0.0001, 0.0006, and 0.0001, respectively). The gene discussed is SYK; the disease is acute myeloid leukemia.